Survivin -31G/C promoter polymorphism and P53 antibodies in breast cancer

Document Type : Original Article

Authors

1 Debartment of Biochemistry, Faculty of Medicine, Sohag University.

2 Department of Medical Biochemistry, Faculty of Medicine,Assiut University.

3 Department of Medical Biochemistry, Faculty of Medicine, Tanta University.

4 Department of Biochemistry, Faculty of Medicine, Sohag University.

Main Subjects

References

  1. Altieri DC.,(2003): Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene ; 22 : 8581-9.
  2. Ambrosini G, Adida C and Altieri DC.,(1997): A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Mad ; 3 : 917-21.
  3. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S.,(1994):  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 480–487.
  4. Be´roud, C., and Soussi, T.(1998):  p53 gene mutation: software and database. Nucleic Acids Res., 26: 200–204.
  5. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. (1987):  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185–189.
  6. Fukuda S and Pelus LM.,(2001): Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood; 98:2091 – 100.
  7. Hoffmann, L.S., Etzrodt, J., Willkomm, L., Sanyal, A., Scheja, L., Fischer, A.W.C., Stasch, J.-P., Bloch, W., Friebe, A., Heeren, J., and Pfeifer, A. (2015). Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat. Commun. 6, 7235.
  8. Khan Z and Bisen PS.,(2013): Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta 2013; 1836 : 123-45. 48.
  9. Lubin, R., Schlichtholz, B., Teillaud, J. L., Garay, E., Bussel, A., Wild, C., and Soussi, T. (1995):  p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin. Cancer Res., 1: 1463–1469.
  10. Reed JC.(2003): Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3: 17-22.
  11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. Jan 2013;63(1):11-30.
  12. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA.J Am Coll Radiol.,(2018): Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. Mar;15(3 Pt A):408-414. DOI: 10.1016/j.jacr.2017.11.034.
  13. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. (1997): Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857–862.
  14. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991): Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345–347.

 

 

 

Files

Share

How to cite

Statistics